Low Glycemic Load Diet in Patients With Stage I-III Colon Cancer

Sponsor
Case Comprehensive Cancer Center (Other)
Overall Status
Completed
CT.gov ID
NCT02129218
Collaborator
National Cancer Institute (NCI) (NIH)
18
2
4
40.7
9
0.2

Study Details

Study Description

Brief Summary

This pilot clinical trial studies the feasibility of a low glycemic load diet in patients with stage I-III colon cancer. A low glycemic load diet includes foods that have low scores on the glycemic index. The glycemic index is a scale that measures how much a certain carbohydrate causes a person's blood sugar to rise. A low glycemic load diet may help decrease the chance of cancer coming back and improve the survival in patients with colon cancer.

Condition or Disease Intervention/Treatment Phase
  • Other: questionnaire administration
  • Other: laboratory biomarker analysis
  • Behavioral: Standard Dietary Intervention
  • Behavioral: Intensified Dietary Intervention
  • Behavioral: Low glycemic load
  • Behavioral: Medium Glycemic Load
N/A

Detailed Description

PRIMARY OBJECTIVES:
  1. To determine the feasibility of following a low or medium glycemic load diet in patients with stage I-III (local-regional) colon cancer.
SECONDARY OBJECTIVES:
  1. To determine patient-reported acceptability of diet. II. To determine nutritionist resources utilized. III. To evaluate the effect of lowering dietary glycemic load on body mass index (BMI), lipid metabolism and pro-oncogenic intermediaries of cellular metabolism.

OUTLINE: Patients are sequentially enrolled in 1 of 4 possible cohorts as needed based on the feasibility of the prior cohort.

COHORT 1: Patients follow a low glycemic load diet with standard dietary intervention (contact with nutritionist in person every 2 weeks with phone contact on the alternating weeks) for 12 weeks.

COHORT 2: Patients follow a low glycemic load diet with intensified dietary intervention (contact with nutritionist in person every week) for 12 weeks.

COHORT 3: Patients follow a medium glycemic load diet with standard dietary intervention for 12 weeks.

COHORT 4: Patients follow a medium glycemic load diet with intensified dietary intervention for 12 weeks.

Study Design

Study Type:
Interventional
Actual Enrollment :
18 participants
Allocation:
Non-Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Supportive Care
Official Title:
A Pilot Study to Determine the Feasibility of a Low Glycemic Load Diet in Patients With Stage I-III Colon Cancer
Actual Study Start Date :
Feb 16, 2015
Actual Primary Completion Date :
Jun 14, 2018
Actual Study Completion Date :
Jul 10, 2018

Arms and Interventions

Arm Intervention/Treatment
Experimental: Cohort 1: Low glycemic load with standard diet

Patients follow a low glycemic load diet with a standard dietary intervention for 12 weeks.

Other: questionnaire administration
Ancillary studies including three day food record, twenty-four hour dietary recall, and a food acceptability questionnaire.

Behavioral: Standard Dietary Intervention
Participants will be contacted by a nutritionist, in person every 2 weeks with phone contact on the alternating weeks. At the initial visit, each participant will be given verbal and written patient education materials, including low glycemic load diet recipes, meal plans, food preparation, and grocery shopping information. Individual instruction will be tailored to their baseline dietary preferences (e.g. vegan, allergies, etc).

Behavioral: Low glycemic load

Experimental: Cohort 2: Low glycemic load with intensified diet

Patients follow a low glycemic load diet with intensified dietary intervention for 12 weeks.

Other: questionnaire administration
Ancillary studies including three day food record, twenty-four hour dietary recall, and a food acceptability questionnaire.

Other: laboratory biomarker analysis
Correlative studies

Behavioral: Intensified Dietary Intervention
Patients will be contacted weekly, in person, by a nutritionist . Participants will take part in a cooking demonstration at the time of their initial visit. The demonstration will be hands-on and participants will be able to sample foods and recipes. In addition to grocery shopping information, participants will be accompanied by a nutritionist to their local grocery store to practice new shopping habits for their target dietary glycemic load. Each participant will also receive weekly random phone calls to assess his or her progress.

Behavioral: Low glycemic load

Active Comparator: Cohort 3: Medium glycemic load with standard diet

Patients follow a medium glycemic load diet with standard dietary intervention for 12 weeks.

Other: questionnaire administration
Ancillary studies including three day food record, twenty-four hour dietary recall, and a food acceptability questionnaire.

Other: laboratory biomarker analysis
Correlative studies

Behavioral: Standard Dietary Intervention
Participants will be contacted by a nutritionist, in person every 2 weeks with phone contact on the alternating weeks. At the initial visit, each participant will be given verbal and written patient education materials, including low glycemic load diet recipes, meal plans, food preparation, and grocery shopping information. Individual instruction will be tailored to their baseline dietary preferences (e.g. vegan, allergies, etc).

Behavioral: Medium Glycemic Load

Active Comparator: Cohort 4: Medium glycemic load with intensified diet

Patients follow a medium glycemic load diet with intensified dietary intervention for 12 weeks.

Other: questionnaire administration
Ancillary studies including three day food record, twenty-four hour dietary recall, and a food acceptability questionnaire.

Other: laboratory biomarker analysis
Correlative studies

Behavioral: Intensified Dietary Intervention
Patients will be contacted weekly, in person, by a nutritionist . Participants will take part in a cooking demonstration at the time of their initial visit. The demonstration will be hands-on and participants will be able to sample foods and recipes. In addition to grocery shopping information, participants will be accompanied by a nutritionist to their local grocery store to practice new shopping habits for their target dietary glycemic load. Each participant will also receive weekly random phone calls to assess his or her progress.

Behavioral: Medium Glycemic Load

Outcome Measures

Primary Outcome Measures

  1. Individual patient compliance, defined by following assigned target glycemic load index >= 75% of the time between weeks 4 and 12 [Up to week 12]

    This compliance rate will be determined through conducting a 24 hour telephone recall, every 2 weeks at random and calculating the glycemic load. For each dose cohort, the number and percentage of patients who are compliant will be summarized, with 90% confidence interval that accounts for the two-stage design.

Secondary Outcome Measures

  1. Food acceptability score [Up to 12 weeks]

    Results of the acceptability survey will be tabulated and described (the questions use a 7 point likert scale), separately for each cohort.

  2. Hours of nutritionist time per week [Up to 12 weeks]

    The median number of hours will be calculated based on time spent with each patient, separately for each cohort.

Other Outcome Measures

  1. Change in serum levels of glycosylated hemoglobin [Baseline to up to 12 weeks]

    Separately for each cohort, serum levels will be summarized descriptively and graphically across the follow-up period. Paired t-tests or Wilcoxon signed rank tests will be used to compare baseline vs. post-intervention levels of all biomarkers. Changes in biomarkers will be correlated with dietary glycemic index (GI) using Pearson or Spearman correlation coefficients, across the follow-up period.

  2. Change in BMI [Baseline to up to 12 weeks]

    Separately for each cohort, BMI levels will be summarized descriptively and graphically across the follow-up period.

  3. Change in serum levels of markers of lipid metabolism [Baseline to up to 12 weeks]

    Separately for each cohort, serum levels will be summarized descriptively and graphically across the follow-up period. Paired t-tests or Wilcoxon signed rank tests will be used to compare baseline vs. post-intervention levels of all biomarkers. Changes in biomarkers will be correlated with dietary GI using Pearson or Spearman correlation coefficients, across the follow-up period.

  4. Change in serum levels of proteins affected by carbohydrate metabolism [Baseline to up to 12 weeks]

    Separately for each cohort, serum levels will be summarized descriptively and graphically across the follow-up period. Paired t-tests or Wilcoxon signed rank tests will be used to compare baseline vs. post-intervention levels of all biomarkers. Changes in biomarkers will be correlated with dietary GI using Pearson or Spearman correlation coefficients, across the follow-up period.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Patients must have stage I-III colon or rectal cancer and have undergone definitive therapy; definitive therapy may have included surgery alone, or surgery plus neoadjuvant and/or adjuvant therapy

  • Patients must regularly consume a diet with a glycemic load > 150 as estimated through the 3 day food recall

  • Patients must readily be available for a 3 month period and agree to participate in regular dietary adherence assessments (surveys and phone interviews)

Exclusion Criteria:
  • Current participation in an intervention targeting diet or exercise

Contacts and Locations

Locations

Site City State Country Postal Code
1 Case Comprehensive Cancer Center Cleveland Ohio United States 44106-5065
2 Metrohealth Medical Center Cleveland Ohio United States 44106

Sponsors and Collaborators

  • Case Comprehensive Cancer Center
  • National Cancer Institute (NCI)

Investigators

  • Study Director: Michelle Treasure, MD, Case Comprehensive Cancer Center

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Case Comprehensive Cancer Center
ClinicalTrials.gov Identifier:
NCT02129218
Other Study ID Numbers:
  • CASE7213
  • NCI-2014-00831
  • CASE7213
  • P30CA043703
First Posted:
May 2, 2014
Last Update Posted:
Jul 20, 2018
Last Verified:
Jul 1, 2018
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jul 20, 2018